ArticleScientific reports2019
Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Cerium oxide nanoparticles attenuate hepatic failure via blocking TGF-β/Smads and upregulating Nrf2/HO-1 signaling pathways in liver fibrosis rat model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems.International journal of nanomedicine · 2026Review
- Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver research (Beijing, China) · 2025Review
- Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease.Asian journal of pharmaceutical sciences · 2025Review
- Combined Esculentin-2CHa Fusion Protein-Coated Au Nanoparticles for Effective Against Non-Alcoholic Fatty Liver Disease in Mice Model.International journal of nanomedicine · 2025Article
- PEG-Coated Ceria-Zirconia Nanoparticle Prevent Weight Gain and Obesity-Related Organ Damage Through Autophagy Flux Activation and ROS Scavenging.International journal of nanomedicine · 2025Article
- Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection.International journal of nanomedicine · 2025Review
- Rising Influence of Nanotechnology in Addressing Oxidative Stress-Related Liver Disorders.Antioxidants (Basel, Switzerland) · 2023Review
- Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration.Antioxidants (Basel, Switzerland) · 2023Article
- Stress mechanism involved in the progression of alcoholic liver disease and the therapeutic efficacy of nanoparticles.Frontiers in immunology · 2023Review
- Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway.Journal of translational medicine · 2022Article
- Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications.Advanced materials (Deerfield Beach, Fla.) · 2022Review
- pH-responsive theranostic nanoplatform of ferrite and ceria co-engineered nanoparticles for anti-inflammatory.Frontiers in bioengineering and biotechnology · 2022Article
- How Does Immunomodulatory Nanoceria Work? ROS and Immunometabolism.Frontiers in immunology · 2022Article
- Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver.Metabolism open · 2021Article
- Cerium Oxide Nanoparticles Alleviate Hepatic Fibrosis Phenotypes In Vitro.International journal of molecular sciences · 2021Article
- Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Cytotoxicity, Retention, and Anti-inflammatory Effects of a CeOACS pharmacology & translational science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles (CeO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.